Nicotine patches and gum sales hit by e-cigs
That bombshell comes from the chief executive of GlaxoSmithKline.
E-cigarettes have become popular with people trying to give up traditional cigarettes, rather than perhaps go down the full cold turkey-style route of gum and patches.
The that's-actually-his-name Andrew Witty, Glaxo’s chief executive reckons vaping has "definitely taken a bit of our market, no question at all".
Witty went on to say that GSK have thought about getting into the electronic cigarette market, although it's all a bit dodgy at the moment, what with the lack of proper scientific data about them.
"We've decided we're not going to play. We've consciously had a think about it but we're not going to play," Witty said. GSK sells various nicotine replacement therapies (NRT) and smoking cessation products, mainly in the form of patches or gum, including the brands Nicorette, NicoDerm CQ and the medicine Zyban.
Makes a nice change for GSK, as they're normally in the press for selling drugs like Paroxetine to kids, pleading guilty to criminal charges and paying out $3 billion for promoting its antidepressants for unapproved uses, getting in trouble with the IRS and a variety of fraud cases in Europe.